Methylated Alteration of SHP1 Complements Mutation of JAK2 Tyrosine Kinase in Patients with Myeloproliferative Neoplasm |
Yang, Jun-Jun
(Department of Laboratory Medicine, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University)
Chen, Hui (Department of Laboratory Medicine, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University) Zheng, Xiao-Qun (Department of Laboratory Medicine, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University) Li, Hai-Ying (Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University) Wu, Jian-Bo (Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University) Tang, Li-Yuan (Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University) Gao, Shen-Meng (Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University) |
1 | Oka T, Ouchida M, Koyama M, et al (2002). Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res, 62, 6390-4. |
2 | Pardanani A, Gotlib JR, Jamieson C, et al (2011). Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol, 29, 789-96. DOI |
3 | Pardanani AD, Levine RL, Lasho T, et al (2006). MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood, 108, 3472-6. DOI |
4 | Pietra D, Li S, Brisci A, et al (2008). Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood, 111, 1686-9. |
5 | Shen SH, Bastien L, Posner BI, et al (1991). A protein-tyrosine phosphatase with sequence similarity to the SH2 domain of the protein-tyrosine kinases. Nature, 352, 736-9. DOI |
6 | Tefferi A, Vainchenker W (2011). Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol, 29, 573-82. DOI |
7 | Tefferi A, Vardiman JW (2008). Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia, 22, 14-22. DOI |
8 | Tyner JW, Bumm TG, Deininger J, et al (2010). CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood, 115, 5232-40. DOI |
9 | Verstovsek S, Kantarjian HM, Estrov Z, et al (2012a). Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood, 120, 1202-9. DOI |
10 | Zhang Y, Zhao D, Zhao H, et al (2012). Hypermethylation of SHP-1 promoter in patient with high-risk myelodysplastic syndrome and it predicts poor prognosis. Med Oncol, 29, 2359-63. DOI |
11 | Benekli M, Baer MR, Baumann H, et al (2003). Signal transducer and activator of transcription proteins in leukemias. Blood, 101, 2940-54. DOI |
12 | Capello D, Deambrogi C, Rossi D, et al (2008). Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. Br J Haematol, 141, 504-11. DOI |
13 | Chim CS, Fung TK, Cheung WC, et al (2004). SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood, 103, 4630-5. DOI |
14 | Gao SM, Chen CQ, Wang LY, et al (2013). Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms. Exp Hematol, 41, 261-70. DOI |
15 | Khoury JD, Rassidakis GZ, Medeiros LJ, et al (2004). Methylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma. Blood, 104, 1580-1. DOI |
16 | Hookham MB, Elliott J, Suessmuth Y, et al (2007). The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood, 109, 4924-9. DOI |
17 | James C, Ugo V, Le Couedic JP, et al (2005). A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 1144-8. DOI |
18 | Jost E, do ON, Dahl E, et al (2007). Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia, 21, 505-10. DOI |
19 | Kumagai C, Kalman B, Middleton FA, et al (2012). Increased promoter methylation of the immune regulatory gene SHP-1 in leukocytes of multiple sclerosis subjects. J Neuroimmunol, 246, 51-7. DOI |
20 | Levine RL, Wadleigh M, Cools J, et al (2005). Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387-97. DOI |
21 | Li LC, Dahiya R (2002). MethPrimer: designing primers for methylation PCRs. Bioinformatics, 18, 1427-31. DOI |
22 | Nakase K, Cheng J, Zhu Q, et al (2009). Mechanisms of SHP-1 P2 promoter regulation in hematopoietic cells and its silencing in HTLV-1-transformed T cells. J Leukoc Biol, 85, 165-74. |
23 | Oh ST, Simonds EF, Jones C, et al (2010). Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood, 116, 988-92. DOI |
24 | Witkiewicz A, Raghunath P, Wasik A, et al (2007). Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma. Hum Pathol, 38, 462-7. DOI |
25 | Verstovsek S, Mesa RA, Gotlib J, et al (2012b). A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 366, 799-807. DOI |
26 | Wang J, Xu Z, Liu L, et al (2013). JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms. Leukemia, 27, 1763-7 DOI |
27 | Wang Y, Fiskus W, Chong DG, et al (2009). Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood, 114, 5024-33. DOI |
28 | Wlodarski P, Zhang Q, Liu X, et al (2007). PU.1 activates transcription of SHP-1 gene in hematopoietic cells. J Biol Chem, 282, 6316-23. |
29 | Xu SB, Liu XH, Li BH, et al (2009). DNA methylation regulates constitutive expression of Stat6 regulatory genes SOCS-1 and SHP-1 in colon cancer cells. J Cancer Res Clin Oncol, 135, 1791-8. DOI |
30 | Xu Z, Gale RP, Zhang Y, et al (2012). Unique features of primary myelofibrosis in Chinese. Blood, 119, 2469-73. DOI |
31 | Zhang J, Somani AK, Siminovitch KA (2000). Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Semin Immunol, 12, 361-78. DOI |
32 | Zhang Q, Wang HY, Marzec M, et al (2005). STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci USA, 102, 6948-53. DOI |